Original Research Article
Donepezil in Alzheimer’s Disease: What to Expect after 3 Years of Treatment in a Routine Clinical SettingWallin Å.K.a · Andreasen N.b · Eriksson S.c · Båtsman S.d · Näsman B.c · Ekdahl A.e · Kilander L.f · Grut M.g · Rydén M.g · Wallin A.h · Jonsson M.h · Olofsson H.i · Londos E.a · Wattmo C.a · Eriksdotter Jönhagen M.b · Minthon L.a
aClinical Memory Research Unit, Department of Clinical Sciences, Malmö, Lund University, Malmö, bKarolinska Institutet, Alzheimer’s Disease Research Center, Department of Neurotec, Division of Geriatric Medicine, Karolinska University Hospital, Huddinge, Stockholm, cSection of Geriatric Medicine, Department of Community Medicine and Rehabilitation, Umeå University, Umeå, dDepartment of Primary Care, Kalix Vårdcentral, Kalix, eDepartment of Geriatric Medicine University Hospital Linköping, Linköping, fDepartment of Public Health and Caring Sciences/Geriatrics, Uppsala University, Uppsala, gDepartment of Geriatric Medicine, Cognitive Section Danderyd Hospital, Danderyd, hInstitute of Neuroscience, Section of Psychiatry, Göteborg/Sahlgrenska University Hospital, Mölndal, and iMemory Clinic, Uddevalla Hospital, Uddevalla, Sweden
Do you have an account?
- Rent for 48h to view
- Buy Cloud Access for unlimited viewing via different devices
- Synchronizing in the ReadCube Cloud
- Printing and saving restrictions apply
Rental: USD 8.50
Cloud: USD 20.00
Article / Publication Details
Background/Aims: Clinical short-term trails have shown positive effects of donepezil treatment in patients with Alzheimer’s disease. The outcome of continuous long-term treatment in the routine clinical settings remains to be investigated. Methods: The Swedish Alzheimer Treatment Study (SATS) is a descriptive, prospective, longitudinal, multicentre study. Four hundred and thirty-five outpatients with the clinical diagnosis of Alzheimer’s disease, received treatment with donepezil. Patients were assessed with Mini-Mental State Examination (MMSE), Alzheimer’s Disease Assessment Scale-cognitive subscale (ADAS-cog), global rating (CIBIC) and Instrumental Activities of Daily Living (IADL) at baseline and every 6 months for a total period of 3 years. Results: The mean MMSE change from baseline was positive for more than 6 months and in subgroups of patients for 12 months. After 3 years of treatment the mean change from baseline in MMSE-score was 3.8 points (95% CI, 3.0–4.7) and the ADAS-cog rise was 8.2 points (95% CI, 6.4–10.1). This is better than expected in untreated historical cohorts, and better than the ADAS-cog rise calculated by the Stern equation (15.6 points; 95% CI, 14.5–16.6). After 3 years with 38% of the patients remaining, 30% of the them were unchanged or improved in the global assessment. Conclusion: Three-year donepezil treatment showed a positive global and cognitive outcome in the routine clinical setting.
© 2007 S. Karger AG, Basel
Article / Publication Details
Copyright / Drug Dosage / DisclaimerCopyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.